skip to main content

RET Fusion NSCLC — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateLung CancerRET Fusion NSCLCSCE Medical Oncology

A 65-year-old man with NSCLC has an RET fusion detected. What targeted therapy is available?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Selpercatinib (selective RET inhibitor) — LIBRETTO-001 showed ORR ~64% in previously treated and ~85% in treatment-naive RET fusion-positive NSCLC; NICE approved

RET fusions occur in ~1-2% of NSCLC. Selpercatinib (LIBRETTO-001) and pralsetinib (ARROW) are selective RET inhibitors with high response rates. Selpercatinib is NICE-approved. CNS activity is also demonstrated.

Reference: NICE selpercatinib; LIBRETTO-001 Drilon et al NEJM 2020